Eleven Biotherapeutics (EBIO – Snapshot Report) suffered a huge setback with its lead pipeline candidate failing in a late-stage study. Meanwhile, companies like bluebird (BLUE – Snapshot Report), Agios (AGIO – Snapshot Report) and Acceleron (XLRN – Snapshot Report) all got encouraging news on the regulatory front. Achillion (ACHN – Snapshot Report) struck a collaboration agreement with Johnson & Johnson […]
11 ways to play biotech
The Fast Money traders discuss 11 ways to play biotech.
On a sluggish Monday for U.S. stocks, some biotechnology names shined. Celgene and Agios jumped nearly 3 percent while biotech-linked funds continued their steady climbs from last year.Acquisitions and breakthroughs abound in a sector brimming with options ripe for growth. Traders on CNBC’s “Fast Money” outlined their […]
The bull market is nearing six years old. It turns out that the biotech sector again managed a huge outperforming year in 2014 as well. The gains of the key biotech exchange traded funds (ETFs) were up in the 40% range, with the NYSE Arca Biotech index up over 45% year-to-date. The equal-weight biotech ETF performed better than the key larger […]
In a market that is infused with headwinds coming from China, Russia and Europe, there is always one group that Jim Cramer can count on: Biotech.In fact, Cramer has been in a heated love affair with biotech for more than 30 years. While you don’t get a rally from them every day, he thinks they are more reliable than any […]
